Insights Into Renal Cell Carcinoma (RCC)

Perspectives on drivers in treatment decisions in the management of RCC

Southeast/FL – February 10, 2022

Faculty Chair

Daniel J. George, MD

Duke Cancer Center, Durham, NC, USA

Central – February 21, 2022

Faculty Chair

Ulka Vaishampayan, MBBS

Karmanos Cancer Center, Detroit, MI, USA

Southwest #1 – February 23, 2022

Faculty Chair

Rana McKay, MD

UC San Diego Medical Center, San Diego, CA, USA

National – March 10, 2022

Faculty Chair

Tian Zhang, MD

Duke Cancer Center, Durham, NC, USA

CO, IA, OR – March 31, 2022

Faculty Chair

Tian Zhang, MD

Duke Cancer Center, Durham, NC, USA

MI, OH – April 12, 2022

Faculty Chair

Stephanie Berg, MD

Loyola University Medical Center, Maywood, IL, USA

CA, AZ, NM, NV – April 28, 2022

Faculty Chair

Sumanta Pal, MD

City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Northeast – June 21, 2022

Faculty Chair

David Braun, MD, PhD

Dana-Farber Cancer Center, Boston, MA, USA

MN, IL – June 29, 2022

Faculty Chair

Ulka Vaishampayan, MBBS

Karmanos Cancer Center, Detroit, MI, USA

Southeast #1 – July 12, 2022

Faculty Chair

Daniel J. George, MD

Duke Cancer Center, Durham, NC, USA

Southeast #2 – September 1, 2022

Faculty Chair

Daniel J. George, MD

Duke Cancer Center, Durham, NC, USA

Southeast #3 – September 21, 2022

Faculty Chair

Asim Bilen, MD

Winship Cancer Institute, Atlanta, GA, USA

Midwest – September 27, 2022

Faculty Chair

Alan Tan, MD

Rush University Medical Center, Chicago, IL, USA

Great Lakes #1 – October 18, 2022

Faculty Chair

Ulka Vaishampayan, MBBS

Karmanos Cancer Center, Detroit, MI, USA

Midwest – October 26, 2022

Faculty Chair

Gautam Jha, MD

Masonic Cancer Clinic, Minneapolis, MN, USA

Great Lakes #2 – November 15, 2022

Faculty Chair

Ulka Vaishampayan, MBBS

Karmanos Cancer Center, Detroit, MI, USA

Mountain – November 16, 2022

Faculty Chair

Elizabeth Wulff-Burchfield, MD

University of Kansas Medical Center, Kansas City, KS, USA

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • National

More Information

  • Virtual series
  • Colorado, Iowa, Oregon

More Information

  • Virtual series
  • California, Arizona, Nevada, and New Mexico

More Information

  • Virtual series
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Virtual series
  • Minnesota, Illinois

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Midwest region

More Information

  • Virtual series
  • Great Lakes

More Information

  • Virtual series
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Virtual series
  • Great Lakes

More Information

  • Virtual series

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of RCC
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.